Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection — United Kingdom and United States, March–August 2020

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Morris, Sapna Bamrah ; Schwartz, Noah G. ; Patel, Pragna ; Abbo, Lilian ; Beauchamps, Laura ; Balan, Shuba ; Lee, Ellen H. ; Paneth-Pollak, Rachel ; Geevarughese, Anita ; Lash, Maura K. ; Dorsinville, Marie S. ; Ballen, Vennus ; Eiras, Daniel P. ; Newton-Cheh, Christopher ; Smith, Emer ; Robinson, Sara ; Stogsdill, Patricia ; Lim, Sarah ; Fox, Sharon E. ; Richardson, Gillian ; Hand, Julie ; Oliver, Nora T. ; Kofman, Aaron ; Bryant, Bobbi ; Ende, Zachary ; Datta, Deblina ; Belay, Ermias ; Godfred-Cato, Shana
• Description:
  During the course of the coronaVirus disease 2019 (COVID-19) pandemic, reports of a new multisystem inflammatory syndrome in children (MIS-C) have been increasing in Europe and the United States (1-3). Clinical features in children have varied but predominantly include shock, cardiac dysfunction, abdominal pain, and elevated inflammatory markers, including C-reactive protein (CRP), ferritin, D-dimer, and interleukin-6 (1). Since June 2020, several case reports have described a similar syndrome in adults; this review describes in detail nine patients reported to CDC, seven from published case reports, and summarizes the findings in 11 patients described in three case series in peer-reviewed journals (4-6). These 27 patients had cardiovascular, gastrointestinal, dermatologic, and neurologic symptoms without severe respiratory illness and concurrently received positive test results for SARS-CoV-2, the Virus that causes COVID-19, by polymerase chain reaction (PCR) or antibody assays indicating recent infection. Reports of these patients highlight the recognition of an illness referred to here as multisystem inflammatory syndrome in adults (MIS-A), the heterogeneity of clinical signs and symptoms, and the role for antibody tTesting in identifying similar cases among adults. Clinicians and health departments should consider MIS-A in adults with compatible signs and symptoms. These patients might not have positive SARS-CoV-2 PCR or antigen test results, and antibody tTesting might be needed to confirm previous SARS-CoV-2 infection. Because of the temporal association between MIS-A and SARS-CoV-2 infections, interventions that prevent COVID-19 might prevent MIS-A. Further research is needed to understand the pathogenesis and long-term effects of this newly described condition.
• Subjects:
  Adult CoronaVirus Infections COVID-19 Female Full Report Humans Male Middle Aged Pandemics Pneumonia, Viral Systemic Inflammatory Response Syndrome Young Adult

  More +
• Source:
  MMWR Morbidity Mortal Weekly Rep. 69(40):1450-1456
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  33031361
• Pubmed Central ID:
  PMC7561225
• Document Type:
  Journal Article
• Place as Subject:
  United Kingdom ; United States
• Pages in Document:
  7 pdf pages
• Volume:
  69
• Issue:
  40
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:60c51f4715f623bbd0c165185562c62c36226d1b31fad34488f2c76c309cd43d487be4725a14e4d3e08167d2b8fc0b9fcfdf75a1a426cc78e65e04e8243ae95b
• Download URL:
  https://stacks.cdc.gov/view/cdc/95813/cdc_95813_DS1.pdf
• File Type:
  [PDF - 399.58 KB ]